Educational reference only. Informational material drawn from peer-reviewed literature. Not medical advice and not a recommendation to use, dose, or modify any therapy. Decisions about hormone therapy should be made with a qualified healthcare provider.
Overview
Overview
BPC-157 (Body Protection Compound 157, also called the stable gastric pentadecapeptide) is a synthetic 15-amino acid peptide derived from a fragment of a protein found in human gastric juice. It is one of the most widely used research peptides in non-medical contexts, with substantial popularity among athletes, bodybuilders, biohackers, and individuals with chronic musculoskeletal injuries.
Despite this widespread use, BPC-157 has essentially no human clinical evidence base: the compound has never been approved by the FDA, has never completed a published Phase 2 or Phase 3 clinical trial, and is not legally available for human consumption through any FDA-regulated channel in the United States.
The disconnect between BPC-157's popularity and its evidence base is unusual and warrants particular attention:
- Animal studies consistently demonstrate dramatic tissue healing effects across multiple injury models (100+ published animal studies)
- Human use is widespread despite no controlled human safety or efficacy data
- The compound exists primarily through unregulated sources and compounded preparations, both of which are legally and regulatorily problematic
- The only published human-use evidence is a 12-patient case series of intra-articular knee injection (Lee & Padgett 2021)
- A Phase 1 safety/PK trial was initiated in 2014–2015 but canceled before publication of results
- FDA placed BPC-157 on its 503A bulk drug substance review list in 2023, effectively limiting legal compounding
- WADA-prohibited under the Prohibited List
Forms
Available forms & half-lives
| Form | Approximate half-life |
|---|---|
| Subcutaneous injection (animal data) | ~30 minutes |
| Intramuscular injection (animal data) | ~30–60 minutes |
| Oral administration (animal data) | Variable; oral bioavailability unclear |
What it does
Main effects
- Tendon healing: accelerated repair across multiple rat models (Achilles, patellar transection/rupture), with improved biomechanical outcomes within 10–14 days (animal evidence only)
- Muscle injury recovery: accelerated fiber regeneration and myotendinous junction repair in animal crush/laceration models
- Bone fracture healing: enhanced union in delayed-healing rat models
- Ligament and soft-tissue repair: broad cytoprotective effects across musculoskeletal injury models
- Gastric and intestinal protection: original research domain; protection against ulceration; inflammatory bowel disease and anastomosis healing models
- Neural recovery: functional recovery in rat spinal cord and sciatic nerve injury models PMC: 6604284
- Knee pain relief (single small case series): 7 of 12 patients reported >6 month relief after single intra-articular injection in the only published human use evidence (Lee & Padgett 2021)
- Proposed mechanism: angiogenesis promotion (VEGFR2 + nitric oxide pathways), growth factor modulation, fibroblast activation, anti-inflammatory effects
What to watch for
Common side effects
- No published human safety data beyond a 12-patient case series: the canceled Phase 1 trial means no human PK or controlled safety data exist
- Theoretical cancer concerns: angiogenesis-promoting mechanism could theoretically promote tumor growth, dormant cancer cell activation, or other angiogenesis-dependent pathologies (diabetic retinopathy, etc.); this is the most significant unaddressed safety concern
- Quality and purity concerns are severe: all supply derives from unregulated sources or compounding (the latter increasingly restricted); identity, concentration, sterility, and storage stability vary dramatically; counterfeits documented
- Injection site reactions: pain, swelling, redness reported anecdotally
- Infection risk: particularly with non-pharmaceutical-grade injectable products
- Mild GI effects: nausea, GI upset reported variably
- Mild fatigue, headache: reported occasionally in non-medical use
- Theoretical immune-modulating effects: unstudied
- No long-term human safety data: multi-year continuous use entirely uncharacterized
- WADA-prohibited: substantial sanctions for athletes subject to anti-doping testing
- Legal/regulatory uncertainty: FDA 503A action (2023) restricts compounding; research chemical sale exists in legal grey area; human consumption is outside any approved channel
Key facts
Key facts worth knowing
- BPC-157 is derived from a 15-amino acid fragment of human gastric juice protein. The original research, conducted primarily by Sikiric and colleagues at the University of Zagreb in Croatia since the 1990s, isolated this peptide fragment and demonstrated it had protective effects against gastric ulcers and various other tissue injuries in animal models.
- The compound has been extensively studied in animal models (rats, mice, and other species) with consistent demonstration of effects on tendon healing, muscle healing, bone healing, intestinal repair, neural recovery, and other tissue regeneration. Over 100 published animal studies investigate various aspects of BPC-157 pharmacology and effects.
- Human clinical evidence is essentially absent. A Phase 1 safety/PK trial was initiated in 2014–2015 but canceled before completion (results were submitted to ClinicalTrials.gov on May 23, 2016, but the study itself is listed as canceled, indicating the sponsor recalled the submission before quality control review).
- One small observational study in 12 patients with chronic knee pain reported 7 of 12 patients experienced relief lasting >6 months after a single BPC-157 knee injection. This is the only human-use evidence in published literature (Lee & Padgett 2021). Lee E, Padgett B. Altern Ther Health Med 2021;27(4):8-13
- The FDA placed BPC-157 on its 503A bulk drug substance review list in 2023, effectively limiting legal compounding of BPC-157 through licensed pharmacies. This restricted one of the previous legal grey area channels for human-grade BPC-157 access. The FDA's position is that BPC-157 is an unapproved new drug for which sufficient evidence of safety and efficacy does not exist to support compounding for human use.
- WADA status: BPC-157 is prohibited under the WADA Prohibited List. Athletes subject to WADA testing must avoid the compound. Detection methodology has been progressively refined for anti-doping purposes.
- A 2025 systematic review (Vasireddi et al., HSS Journal) examined 36 studies on BPC-157 from 1993–2024 and concluded: "BPC-157 could help heal musculoskeletal injuries, but there are potential risks due to unregulated production and lack of clinical safety data."
Legal status
Legal status
No FDA approval. Sale for human consumption is illegal in the United States. Sale for "research purposes" exists in legal grey area. Compounding through 503A pharmacies effectively restricted since 2023 FDA action. Possession for personal use is in regulatory grey area but using for human consumption is outside any approved channel. WADA-prohibited.